ArticleBMC cancer2025
Real-world effectiveness and prognostic factors of platinum rechallenge in advanced urothelial cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the real-world effectiveness and prognostic factors of platinum rechallenge therapy in patients with locally advanced or metastatic urothelial carcinoma (la/mUC), with particular attention to DNA damage response (DDR) pathway gene alterations.
methodsWe retrospectively analyzed 78 patients with la/mUC who received platinum rechallenge therapy across three tertiary referral hospitals in Korea. Clinical outcomes, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), were assessed. Prognostic factors were identified using univariate and multivariate analyses. The impact of DDR pathway gene alterations on treatment response was also evaluated in patients with available data.
resultsThe ORR of platinum rechallenge was 42.3%, with median PFS and OS of 4.7 and 9.0 months, respectively. ORR was numerically higher in ECOG 0–1 versus ≥ 2 (48.2% vs. 27.3%), and in patients without versus with liver metastasis (45.2% vs. 31.2%). Multivariable Cox regression analysis identified ECOG performance status ≥ 2 and liver metastasis as independent adverse prognostic factors. DDR pathway alterations were present in approximately 30% of patients but showed no correlation with ORR, PFS, or OS.
conclusionPlatinum rechallenge demonstrated meaningful clinical activity in selected patients with la/mUC. Clinical factors such as performance status and liver metastasis may help identify patients most likely to benefit. Although DDR pathway alterations were common, they were not associated with treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.